Our study thus points to the increase in Glu and GLX together with the drop in 2-HG as potential translatable early metabolic biomarkers of glioma response to mutant IDH inhibition, which, in combination with the monitoring of tumor volume, could serve to enhance the reliability of noninvasive monitoring of response to mutant IDH inhibitors. This evidence concerns the gene IDH1 and glioma.